Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. (IGC) is at the forefront of developing innovative phytocannabinoid-based therapies aimed at treating a wide range of therapeutic indications. The company is involved in cutting-edge research to develop treatments for conditions such as neuropathic and cancer pain, epilepsy, and chronic neurological and oncological diagnoses, which can be life-altering or life-threatening. The mission of IGC Pharma is to alleviate pain, PTSD, seizures, cachexia, and other severe conditions through advanced cannabinoid-based formulations.
One of the primary focuses of IGC Pharma is to combat Alzheimer's disease. The company has developed two investigational drug assets, IGC-AD1 and TGR-63, that have shown potential in reducing key hallmarks of Alzheimer's, such as plaques and tangles, in cell line studies. IGC-AD1, a low-dose tetrahydrocannabinol-based formulation, is currently undergoing a Phase 2 clinical trial involving 146 participants to evaluate its efficacy in treating agitation in dementia due to Alzheimer's.
Beyond Alzheimer's treatment, IGC Pharma also addresses women's health through its wellness brand Holief, which provides relief for premenstrual syndrome and menstrual cramps. This diversified approach highlights the company’s commitment to improving quality of life across various patient demographics.
IGC Pharma's innovative research and development are complemented by strategic partnerships and a robust product portfolio, which collectively enhance its market presence and potential for growth.
IGC Pharma (NYSE American: IGC) has announced promising preclinical research on IGC-1C, a novel small-molecule modulator. The findings reveal that IGC-1C targets tau protein phase separation, offering new possibilities for treating neurodegenerative diseases. Additionally, IGC-1C has been identified as a potential GLP-1 receptor agonist, showing promise for weight loss treatments and presenting a unique strategy to combat Alzheimer's disease.
Key points:
- IGC-1C exhibits a dissociation constant (Kd) of 3.95 ± 0.32 μM with tau, indicating strong binding affinity
- The molecule effectively inhibits tau condensates and prevents their transition into toxic fibrils
- IGC-1C's dual action targets both tau and GLP-1 receptors, potentially addressing multiple pathways in Alzheimer's and metabolic disorders
- The company aims to advance IGC-1C through future clinical trials
IGC Pharma (NYSE American: IGC) has announced that its proprietary molecule, IGC-1A, has been identified as a potential GLP-1 agonist through AI modeling. This discovery marks a significant milestone for the company, potentially expanding its portfolio to include metabolic disorders and weight loss treatments. GLP-1 agonists are known for managing blood sugar levels and promoting weight loss, with potential neuroprotective benefits for Alzheimer's disease.
CEO Ram Mukunda highlighted that IGC-1A and IGC-1C could become effective options for metabolic disorders, comparing favorably to established drugs like Ozempic and Metformin. The company plans to progress with toxicology and dosing studies in 2024, aiming to submit an Investigational New Drug Application to the FDA for IGC-1A.
IGC Pharma reported its Q1 FY2025 results, highlighting significant progress in its Alzheimer's research portfolio. The company's lead drug candidate, IGC-AD1, showed promising interim data in its Phase 2 clinical trial for agitation in Alzheimer's. Additionally, TGR-63 demonstrated positive pre-clinical results in an Alzheimer's mouse model. Despite these advancements, IGC's revenue decreased by 51% to $272,000 compared to the same period last year. The company's R&D expenses increased by 19% to $889,000, reflecting the expansion of clinical trials. The net loss for the quarter was $2.4 million or $0.03 per share. IGC also extended its $12 million loan agreement with O-Bank for another year.
IGC Pharma (NYSE American: IGC) has announced that Alliance Global Partners (AGP) has initiated analyst coverage on the company's common stock with a 'Buy' recommendation and a $3.50 price target. This coverage represents an independent analysis of IGC Pharma's potential in the market. The company emphasizes that the views expressed in the analyst report are those of AGP and not necessarily reflective of IGC Pharma's own perspectives. IGC Pharma also clarifies that it is not responsible for the content, accuracy, or timeliness of the information provided by analysts. Interested parties can access the full analyst report directly from Alliance Global Partners through a provided link.
IGC Pharma has announced promising preclinical data for its drug candidate TGR-63, targeting Alzheimer’s disease. Studies indicate that TGR-63 can cross the blood-brain barrier, a critical challenge in treating Alzheimer's, as confirmed through mass spectrometry and an octanol-water assay. The drug also demonstrated a favorable safety profile, with no adverse effects observed in mice after eight months. The company plans to advance TGR-63 into clinical trials, presenting it as a potential safer alternative to existing treatments. IGC is also exploring other disease targets using AI-driven analyses.
IGC Pharma announced promising preclinical results for its Alzheimer's therapeutic candidate, TGR-63. In mouse models, TGR-63 demonstrated a significant reduction in amyloid plaques—78% in the cortex and 85% in the hippocampus. This indicates potential for slowing or reversing Alzheimer's progression. TGR-63's effectiveness in disrupting amyloid beta aggregates and promoting neuronal viability was observed in cell cultures. The company plans to begin Phase 1 clinical trials for TGR-63 by 2025. IGC Pharma continues to develop its robust pipeline of Alzheimer's treatments, with a focus on leveraging AI for early disease detection and trial optimization.
IGC Pharma, a clinical-stage pharmaceutical company, released its financial results for the fiscal year ending March 31, 2024. The company reported a revenue increase to $1.3 million, primarily from its Life Sciences segment. There was a notable decrease in SG&A expenses by 21% to $6.7 million. However, R&D expenses rose by 9% to $3.8 million due to ongoing clinical trials. The company had a net loss of $13 million, reflecting a $3.3 million one-time impairment. Significant achievements include positive interim results from the Phase 2 trial of IGC-AD1, promising preclinical data for TGR-63, and securing three new patents. Additionally, IGC signed a cooperation agreement with the University of Los Andes for AI research in pharmaceuticals. The company also raised $6 million through share purchases and secured a $12 million credit line to support expanded operations.
IGC Pharma announced that CEO Ram Mukunda and CCO Claudia Grimaldi will participate in a fireside chat hosted by Ascendiant Capital Markets on June 27, 2024, at 12:00 pm ET. They will discuss recent achievements and upcoming milestones. IGC Pharma focuses on developing treatments for Alzheimer's disease with a pipeline that includes five drug candidates. Notably, IGC-AD1 is in Phase 2 clinical trials targeting agitation in dementia associated with Alzheimer's, while other candidates like TGR-63, IGC-M3, and IGC-1C are in preclinical stages. The company also leverages AI for Alzheimer's research.
IGC Pharma announced a new study published in the European Society of Medicine Journal examining the impact of CYP2C9 genetic polymorphisms on the pharmacokinetics of delta-9-tetrahydrocannabinol (THC) in Alzheimer's patients. The study, conducted with Puerto Rican participants, revealed significant variations in THC metabolism among different genetic profiles, underscoring the importance of personalized medicine.
IGC is currently in Phase 2 trials of IGC-AD1, a THC-based drug candidate aimed at treating agitation in Alzheimer's patients. The research aligns with IGC's commitment to include underrepresented populations and develop innovative treatments. CEO Ram Mukunda and lead scientist Dr. Jagadeesh S. Rao highlighted the study's importance for personalized dosing strategies in Alzheimer's care.
IGC Pharma has commenced patient enrollment at Neurostudies in Port Charlotte, Florida, for its Phase 2 clinical trial of IGC-AD1, a THC-based formulation aimed at treating agitation in Alzheimer's patients. The trial, involving 146 participants, will assess the efficacy of IGC-AD1, which targets neuroinflammation and neurotransmitter imbalances. Neurostudies, led by Dr. Liliana Montoya and Dr. George Li, brings over 20 years of clinical research experience.
Two patients were enrolled in May 2024, marking a significant milestone for IGC Pharma. The company has 11 more trial sites under contract in the U.S. and Canada. Ram Mukunda, CEO of IGC Pharma, emphasized the company's commitment to advancing Alzheimer's therapies. IGC Pharma's pipeline includes five drug candidates aimed at different aspects of Alzheimer's pathology.
FAQ
What is the current stock price of IGC Pharma (IGC)?
What is the market cap of IGC Pharma (IGC)?
What is the main focus of IGC Pharma, Inc.?
What are IGC Pharma's key investigational drug assets for Alzheimer's?
What is the status of IGC-AD1?
Does IGC Pharma have products targeting women's health?
What conditions does IGC Pharma aim to treat with its therapies?
How does IGC Pharma contribute to Alzheimer's research?
What is the mission of IGC Pharma?
What is the significance of IGC's research on neuropathic and cancer pain?
Does IGC Pharma have any products in the wellness market?
What makes IGC Pharma unique in the biotech industry?
